Tiziana Life Sciences Ltd (TLSA)

Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy

Tiziana doses first three patients in ALS trial of nasal antibody foralumab

Tiziana Life Sciences completes patient visits in Phase 2a MS drug trial

Tiziana Life Sciences partners with Saudi institutions on MS combination therapy trial

Tiziana Life Sciences gets Buy rating from BTIG on Treg-based approach to neurodegeneration

Dow climbs as stocks rebound on earnings, falling Treasury yields

Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026

Tiziana Life Sciences Announces Poster Presentation on Phase 2a BANYAN Clinical Trial of Intranasal Foralumab at ALS Nexus 2026

Gemini Pro delay leaves Google with an empty flagship tier

Tiziana Life Sciences announces CEO share purchase

Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer

Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition

Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient

Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman